Evidence map›Paper›PMID 39308301›Full record

ArticleBJPsych open2024

Characteristics of high-dose benzodiazepine use: nationwide cohort study on new benzodiazepine users with 5-year follow-up.

Hanna Särkilä, Heidi Taipale, Antti Tanskanen, Terhi Kurko, Tero Taiminen, Jari Tiihonen, Reijo Sund, Leena Saastamoinen, Jarmo Hietala, Solja Niemelä

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BJPsych open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Hanna SärkiläDepartment of Psychiatry, Clinical Institute, University of Turku, Turku, Finland.ORCID https://orcid.org/0000-0002-5819-0586
Heidi TaipaleDepartment of Forensic Psychiatry, University of Eastern Finland, Niuvanniemi Hospital, Kuopio, Finland.ORCID https://orcid.org/0000-0002-3281-934X
Antti TanskanenDepartment of Forensic Psychiatry, University of Eastern Finland, Niuvanniemi Hospital, Kuopio, Finland.
Terhi KurkoResearch Unit, The Social Insurance Institution, Helsinki, Finland.
Tero TaiminenDepartment of Psychiatry, Clinical Institute, University of Turku, Turku, Finland.
Jari TiihonenDepartment of Forensic Psychiatry, University of Eastern Finland, Niuvanniemi Hospital, Kuopio, Finland.
Reijo SundSchool of Pharmacy, University of Eastern Finland, Kuopio, Finland.
Leena SaastamoinenInformation and Development Services, Finnish Medicines Agency, Helsinki, Finland.
Jarmo HietalaDepartment of Psychiatry, Clinical Institute, University of Turku, Turku, Finland.ORCID https://orcid.org/0000-0002-3179-6780
Solja NiemeläDepartment of Psychiatry, Clinical Institute, University of Turku, Turku, Finland.ORCID https://orcid.org/0000-0003-1130-9161

Funding

AlkoholitutkimussäätiöTurun Yliopistollisen Keskussairaalan Koulutus- ja Tutkimussäätiö Grant P3704
6 · The paper itself

Abstract

backgroundA nationwide register-based cohort study from Finland including 48 124 incident benzodiazepines and related drug (BZDR) users aged 18-65 years who initiated use in 2006 and were not dispensed BZDRs during 2004-2005. The follow-up was 5 years or until death, whichever occurred first.

aimsTo investigate sociodemographic and clinical factors associated with high-dose use of BZDRs (i.e. Z-drugs) among new BZDR users.

methodThe temporal BZDR dose was calculated as a point estimate every 6 months after initiation as defined daily doses (DDDs) per day, based on the PRE2DUP method (an approach based on mathematical modelling of personal drug purchasing behaviours). Sociodemographic and clinical factors associated with dose categories were studied using multinomial logistic regression.

resultsDuring the 5-year follow-up, very high-dose BZDR use was observed in 7.4% (

conclusionsClinicians should be aware of the dose escalation risk especially when prescribing diazepam, alprazolam or clonazepam for psychiatric indications. If BZDRs are needed, our findings suggest favouring oxazepam.

Indexed as

Benzodiazepinescomorbidityhigh-dose usesociodemographic factorsZ-drugs

Identifiers

PMID39308301
PMCPMC11457226

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.